This paper presents the results on excretion of bismuth after injection of bismuth sodium tartrate, a water-soluble compound in aqueous medium, in the same way as those in previous papers on bismuth metal1 and on potassium bismuth tartrate and bismuth salicylate.2 The bismuth sodium tartrate marketed by Searle and Company of Chicago was used; this consisted of a 1.5 per cent solution of the bismuth compound in 25 per cent sucrose solution containing 4 per cent of benzyl alcohol, as a local anesthetic. The bismuth content was 73.8 per cent, by analysis. The product was injected intramuscularly in eleven confined and ambulatory patients, seven of whom had cerebrospinal syphilis, and four variable degrees of edema of circulatory or hepatic origin without syphilis. The latter patients served as the subjects in a study of the diuretic action of the product, described in a previous paper,3 which also contained
HANZLIK PJ, MEHRTENS HG, MARSHALL DC, WATSON F, SPAULDING J. CLINICAL EXCRETION OF BISMUTH: BISMUTH SODIUM TARTRATE. Arch Derm Syphilol. 1930;22(5):850–860. doi:10.1001/archderm.1930.01440170076009
Dermatology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.